Author: Moal, Valérie; Zandotti, Christine; Colson, Philippe
Title: Emerging viral diseases in kidney transplant recipients Cord-id: 5uoc3y4r Document date: 2012_11_7
ID: 5uoc3y4r
Snippet: Viruses are the most important cause of infections and a major source of mortality in Kidney Transplant Recipients (KTRs). These patients may acquire viral infections through exogenous routes including community exposure, donor organs, and blood products or by endogenous reactivation of latent viruses. Beside major opportunistic infections due to CMV and EBV and viral hepatitis B and C, several viral diseases have recently emerged in KTRs. New medical practices or technologies, implementation of
Document: Viruses are the most important cause of infections and a major source of mortality in Kidney Transplant Recipients (KTRs). These patients may acquire viral infections through exogenous routes including community exposure, donor organs, and blood products or by endogenous reactivation of latent viruses. Beside major opportunistic infections due to CMV and EBV and viral hepatitis B and C, several viral diseases have recently emerged in KTRs. New medical practices or technologies, implementation of new diagnostic tools, and improved medical information have contributed to the emergence of these viral diseases in this special population. The purpose of this review is to summarize the current knowledge on emerging viral diseases and newly discovered viruses in KTRs over the last two decades. We identified viruses in the field of KT that had shown the greatest increase in numbers of citations in the NCBI PubMed database. BKV was the most cited in the literature and linked to an emerging disease that represents a great clinical concern in KTRs. HHVâ€8, PVB19, WNV, JCV, H1N1 influenza virus A, HEV, and GB virus were the main other emerging viruses. Excluding HHV8, newly discovered viruses have been infrequently linked to clinical diseases in KTRs. Nonetheless, pathogenicity can emerge long after the discovery of the causative agent, as has been the case for BKV. Overall, antiviral treatments are very limited, and reducing immunosuppressive therapy remains the cornerstone of management. Copyright © 2012 John Wiley & Sons, Ltd.
Search related documents:
Co phrase search for related documents- activity peak and acute syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
- activity peak and liver disease: 1, 2
- activity peak and low incidence: 1
- acute cellular rejection and liver disease: 1
- acute form and liver disease: 1, 2, 3
- acute hepatitis and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute hepatitis and low incidence: 1, 2
- acute pancreatitis and liver disease: 1, 2, 3
- acute pancreatitis and low incidence: 1, 2
- acute renal failure and liver disease: 1, 2, 3, 4, 5
- acute renal failure and low incidence: 1, 2
- acute respiratory virus and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute respiratory virus and low incidence: 1, 2
- acute syndrome and liver abnormality: 1, 2
- acute syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute syndrome and liver enzyme level: 1, 2
- acute syndrome and locally acquire: 1
- acute syndrome and locally acquire disease: 1
Co phrase search for related documents, hyperlinks ordered by date